ASCENTAGE PHARMA GROUP INTERNATIONAL

亞盛醫藥集團

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6855)

Ascentage Pharma to Present Latest Results from Six Preclinical Studies at American Association for Cancer Research (AACR) Annual Meeting 2022

Ascentage Pharma Group International (the "**Company**" or "**Ascentage Pharma**") is pleased to announce that the results from six preclinical studies of the Company's five drug candidates under development: the Bcl-2 inhibitor lisaftoclax (APG-2575) and the MDM2-p53 inhibitor alrizomadlin (APG-115), two key products of the Company's apoptosis-targeted pipeline as well as the FAK inhibitor APG-2449, the EED inhibitor APG-5918 and the KRAS Inhibitor APG-1842, have been selected for presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022, and the abstracts of which have already been published on AACR's official website.

The AACR annual meeting is one of the world's largest and longest-standing scientific gatherings in the field of cancer research. Covering some of the most cutting-edge advances in all the areas of oncology research and innovation, the annual event attracts tremendous interest from the global cancer research community. This year's AACR annual meeting will be held in the city of New Orleans, United States, from April 8 to April 13, 2022.

These six abstracts from Ascentage Pharma include:

Our drug candidates lisaftoclax (APG-2575) and alrizomadlin (APG-115)

Co-targeting MDM2-p53 and BCL-2 apoptosis pathways overcomes resistance conferred by acquired BCL-2 gene mutations in preclinical models

- Abstract Number: 3964
- Session Category: Experimental and Molecular Therapeutics

- Session Title: Hematological and Pediatric Malignancy and Sarcoma Treatment Resistance

- Time: 9:00 AM — 12:30 PM CST, April 13, 2022

BCL-2 mutation is a key mechanism driving the drug-resistance to BCL-2 inhibitors. This study finds that dual targeting the BCL-2 and MDM2-p53 apoptotic pathways can overcome this drug resistance, thereby provide compelling rationale to future clinical studies and a potential clinical strategy for addressing resistance to BCL-2 inhibitors.

Our drug candidate alrizomadlin (APG-115)

Inhibition of MDM2-p53 interaction by alrizomadlin (APG-115) induces pyroptotic cell death in gasdermin E (GSDME)-expressing cancer cells

- Abstract Number: 2998

- Session Category: Molecular/Cellular Biology and Genetics

- Session Title: Non-apoptotic Cell Death/Autophagy

- Time: 1:30 PM — 5:00 PM CST, April 12, 2022

This study revealed a new mechanism of the MDM2-p53 inhibitor APG-115, other than apoptosis induction. The newly discovered mechanism allows APG-115 to induce pyroptotic cell death and the release of inflammatory cytokines in gasdermin E (GSDME)-expressing cancer cells.

MDM2 inhibitor alrizomadlin (APG-115) stabilizes p53 and synergizes with proteasome inhibitors in multiple myeloma

- Abstract Number: 5439

- Session Category: Experimental and Molecular Therapeutics

- Session Title: Small Molecule Therapeutic Agents

- Time: 12:00 PM — 1:00 PM CST, April 8, 2022

This study shows that the MDM2-p53 inhibitor APG-115 in combination with proteasome inhibitor has synergistic antitumor activity in models of TP53 wild-type multiple myeloma.

Our drug candidate APG-2449

FAK inhibitor APG-2449 and CDK4/6 inhibitor palbociclib synergistically suppress mesothelioma tumor growth via autophagy induction

- Abstract Number: 2563
- Session Category: Experimental and Molecular Therapeutics
- Session Title: Cell Cycle, Replication Inhibitors, and Immunotherapy Agents
- Time: 9:00 AM — 12:30 PM CST, April 12, 2022

This study shows that in mesothelioma tumor models, the FAK inhibitor APG-2449 can suppress tumor growth via autophagy induction and has demonstrated antitumor activities, thus provide theoretical support to the design of future clinical studies.

Our drug candidate APG-5918

Preclinical development of embryonic ectoderm development (EED) inhibitor APG-5918/EEDi-5273 for cancer therapy

- Abstract Number: 3939
- Session Category: Experimental and Molecular Therapeutics
- Session Title: Emerging New Anticancer Agents
- Time: 9:00 AM — 12:30 PM CST, April 13, 2022

This study finds that as a potent EED inhibitor, APG-5918 can specifically suppress the H3K27me3 level in tumor cells and has demonstrated potent antitumor activity in EZH2-mutant or SMARCB1-defficient tumor cells and mouse models.

Onur drug candidate APG-1842

Development of covalent KRASG12C inhibitor APG-1842 for the treatment of solid tumors

- Abstract Number: 2664
- Session Category: Experimental and Molecular Therapeutics

- Session Title: Signaling Pathway Inhibitors

- Time: 9:00 AM — 12:30 PM CST, April 12, 2022

This study shows that as a novel selective covalent KRASG12C inhibitor, APG-1842 can block the KRAS signaling-pathway by specially targeting the inactive (GDP bound) KRASG12C protein, demonstrating potent antitumor activity in KRASG12C-mutant tumor cells and mouse tumor models.

About Ascentage Pharma

Ascentage Pharma is a China-based, globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, CHB (Chronic hepatitis B), and age-related diseases. On October 28, 2019, Ascentage Pharma became listed on the Main Board of The Stock Exchange of Hong Kong Limited with the stock code: 6855.HK.

Ascentage Pharma has its own platform for developing therapeutics that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Company has built a pipeline of eight type I small molecule clinical drug candidates which have entered the clinical development stage, including novel, highly potent Bcl-2, and dual Bcl-2/Bcl-xL inhibitors, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors (TKIs). Ascentage Pharma is also the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators. The Company is conducting more than 50 Phase I/II clinical trials in China, the US, Australia and Europe. Olverembatinib, the Company's core drug candidate developed for the treatment of drug-resistant chronic myeloid leukemia (CML), was granted Priority Review status and a Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA), and is already approved for the indication. In addition, Olverembatinib has also been granted an Orphan Drug Designation (ODD) and a Fast Track Designation (FTD) by the US FDA, and an Orphan Designation by the EU. As at the date of this announcement, Ascentage Pharma has obtained a total of 13 ODDs from the US FDA and 1 ODD from the EU for four of the Company's investigational drug candidates. The Company has been designated for multiple major national R&D projects in China, including five Major New Drug Development Projects, one Enterprise Innovative Drug Incubator Base status, four Innovative Drug Research and Development Programs, and one Major Project for the Prevention and Treatment of Infectious Diseases.

Leveraging its robust research and development capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights, and entered into global partnerships with numerous leading biotechnology and pharmaceutical companies and research institutes such as UNITY Biotechnology, MD Anderson Cancer Center, Mayo Clinic, Dana-Farber Cancer Institute, MSD, and AstraZeneca. The Company has built a global and talented team with experience in the research and development of innovative drugs and clinical development, and is setting up its commercial manufacturing and sales and marketing teams with high standards. Ascentage Pharma aims to continuously strengthen its research and development capabilities and accelerate the clinical development progress of its product pipeline to fulfil its mission of 'addressing unmet clinical needs of patients in China and around the world' for the benefit of more patients.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: We cannot guarantee that we will be able to obtain further approval for, or ultimately market, APG-2575, APG-115, APG-2449, APG-5918 and APG-1842 successfully.

By order of the Board
Ascentage Pharma Group International
Dr. Yang Dajun
Chairman and Executive Director

Suzhou, People's Republic of China, March 9, 2022

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Yang Dajun as Chairman and executive Director, Dr. Wang Shaomeng, Dr. Tian Yuan, Dr. Lu Simon Dazhong and Mr. Liu Qian as non-executive Directors, and Mr. Ye Changqing, Dr. Yin Zheng, Mr. Ren Wei and Dr. David Sidransky as independent non-executive Directors.